About vaxart - VXRT
Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.
VXRT At a Glance
Vaxart, Inc.
170 Harbor Way
South San Francisco, California 94080
| Phone | 1-650-550-3500 | Revenue | 28.70M | |
| Industry | Biotechnology | Net Income | -66,948,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 288.942% | |
| Fiscal Year-end | 12 / 2025 | Employees | 115 | |
| View SEC Filings |
VXRT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.663 |
| Price to Book Ratio | 2.559 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.703 |
| Enterprise Value to Sales | 3.672 |
| Total Debt to Enterprise Value | 0.221 |
VXRT Efficiency
| Revenue/Employee | 249,565.217 |
| Income Per Employee | -582,156.522 |
| Receivables Turnover | 2.398 |
| Total Asset Turnover | 0.222 |
VXRT Liquidity
| Current Ratio | 0.751 |
| Quick Ratio | 0.751 |
| Cash Ratio | 0.569 |
VXRT Profitability
| Gross Margin | 84.669 |
| Operating Margin | -230.986 |
| Pretax Margin | -232.362 |
| Net Margin | -233.268 |
| Return on Assets | -51.854 |
| Return on Equity | -114.706 |
| Return on Total Capital | -81.436 |
| Return on Invested Capital | -87.58 |
VXRT Capital Structure
| Total Debt to Total Equity | 39.515 |
| Total Debt to Total Capital | 28.323 |
| Total Debt to Total Assets | 13.994 |
| Long-Term Debt to Equity | 27.403 |
| Long-Term Debt to Total Capital | 19.641 |